We believe policymakers should focus on those issues that directly impact patients, such as PBM regulation and reform, standard plan designs with reasonable deductibles and nominal copays, and ensuring copay assistance counts. We realize that Illinois has taken many of these steps already, and that Illinois policymakers are advocating for change at the national level, too, but more can be done.
Given the importance—and immense cost—of developing new treatments and cures, Amici have a profound interest in ensuring that the law not disincentivize innovation. Amici were accordingly concerned to learn of the new legal duty recognized by the Court of Appeal in this case, which would impose liability on manufacturers of drugs that are undisputedly safe and effective as approved by the FDA itself. The new duty is indifferent to the safety of the existing product, imposing liability if a manufacturer “knew” it could potentially make an even “safer” alternative.
The HIV+Hepatitis Policy Institute urges all members of the House of Representatives to oppose the FY24 Labor HHS Appropriations Bill (HR 5894) due to the $767 million in cuts to HIV domestic prevention and treatment programs, massive cuts to other related programs, and the many damaging social policy riders that are directed to the communities most impacted by HIV.
On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of H.1085/S.619: An Act to address barriers to HIV prevention medication. We need to ensure that everyone is able to benefit from the results of the latest scientific innovations in HIV prevention. We urge the passage of this important bill to ensure that all Bay Staters using commercial insurance can access PrEP without a financial barrier or delay.
As part of $767 million of domestic HIV prevention and treatment funding cuts included in the House Labor, HHS Appropriations bill is the total elimination of a program initiated by the Trump administration that is a critical component of the Ending the HIV Epidemic program. The Primary Care HIV Prevention (PCHP) program provides funding to HRSA’s community health centers in the communities most impacted by HIV to conduct activities to support and provide PrEP, which are highly effective medications that prevent HIV.